DJIA 16,204.97 0.00 0.00%
NASDAQ 4,363.14 0.00 0.00%
S&P 500 1,880.05 0.00 0.00%
market minute promo

Novartis (NYSE: NVS)

72.79 -1.54 (-2.07%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

NVS $72.79 -2.07%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $74.96
Previous Close $74.33
Daily Range $73.97 - $75.08
52-Week Range $73.97 - $106.84
Market Cap $174.4B
P/E Ratio 20.29
Dividend (Yield) $2.67 (3.1%)
Ex-Dividend Date
Dividend Pay Date
02/24/16
01/01/70
Volume 2,306,299
Average Daily Volume 2,350,596
Current FY EPS $5.19

Sector

Healthcare

Industry

Drug Makers

Novartis (NVS) Description

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products. Website: http://www.novartis.com/

News & Commentary Rss Feed

3 Potential Blockbusters Moving the Needle for Big Pharma in 2016

These pharmas have some recently approved drugs that could singlehandedly boost total sales this year.

Pre-Market Most Active for Feb 8, 2016 : CBX, NVS, TVIX, AZN, NOK, MT, BCRX, QQQ, FB, XIV, BAC, APO

Pre-Market Most Active for Feb 8, 2016 : CBX, NVS, TVIX, AZN, NOK, MT, BCRX, QQQ, FB, XIV, BAC, APOL

Biogen Inc. Takes Aim at Johnson & Johnson

Biogen's Samsung Bioepis has Remicade in its crosshairs.

Why Ophthotech Corporation Shares Tumbled 31% in January

The launch of trials in dry age-related macular degeneration failed to spark shares last month.

Valeant's Share Price Continues to Decline

CAH Named Top 25 SAFE Dividend Stock Increasing Payments For Decades

NVS Named Top 10 SAFE International Dividend Stock

Glaxo Tops Q4 Earnings, Revenues Rise Y/Y, 2016 View Intact

ImmunoGen, Inc.'s Earnings Play the Amortization Blues

Keep focused on the pipeline because revenue and earnings are going to be bumpy for some time.

Noteworthy ETF Outflows: VEU, NSRGY, NVS, TM

See More NVS News...

NVS's Top Competitors

NVS $72.79 (-2.07%)
Current stock: NVS
JNJ $100.71 (0.17%)
Current stock: JNJ
MRK $49.21 (-0.35%)
Current stock: MRK
GSK $39.85 (-2.23%)
Current stock: GSK